• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Brust Bernd

    6/10/25 5:26:17 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRVI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Brust Bernd

    (Last) (First) (Middle)
    C/O MARAVAI LIFESCIENCES HOLDINGS, INC.
    10770 WATERIDGE CIRCLE, SUITE 200

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/08/2025
    3. Issuer Name and Ticker or Trading Symbol
    MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Kurt Oreshack, by power of attorney for Bernd Brust 06/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MRVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRVI

    DatePrice TargetRatingAnalyst
    2/26/2025$9.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/19/2024Neutral
    Guggenheim
    12/5/2024$4.25Neutral → Sell
    Goldman
    11/14/2024Peer Perform
    Wolfe Research
    11/8/2024Outperform → Mkt Perform
    William Blair
    8/28/2024$10.00Overweight
    Wells Fargo
    8/13/2024$11.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    4/10/2024$15.00Buy
    Craig Hallum
    More analyst ratings

    $MRVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deford John A bought $100,625 worth of shares (17,500 units at $5.75), increasing direct ownership by 33% to 70,046 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/14/24 4:32:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Hull Carl bought $987,000 worth of shares (175,000 units at $5.64) (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/12/24 4:59:43 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology

      Quantoom's customers can now access TriLink's CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and ma

      6/3/25 10:00:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Financials

    Live finance-specific insights

    See more
    • Maravai Lifesciences Reports First Quarter 2025 Financial Results

      SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance. "Our first quarter revenue exceeded our guidance range, an

      5/12/25 4:06:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.

      5/1/25 7:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne

      3/18/25 4:05:56 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Brust Bernd was granted 2,000,000 shares (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/10/25 5:29:43 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Brust Bernd

      3 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/10/25 5:26:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Herde Kevin was granted 876 shares, increasing direct ownership by 0.13% to 674,636 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      5/28/25 5:52:32 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    SEC Filings

    See more
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      6/9/25 8:40:50 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Maravai LifeSciences Holdings Inc.

      SCHEDULE 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      5/29/25 5:24:04 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      5/28/25 5:26:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/14/24 7:49:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 4:48:49 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 9:30:19 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maravai Life Sciences downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously

      2/26/25 7:15:06 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Maravai Life Sciences

      Guggenheim initiated coverage of Maravai Life Sciences with a rating of Neutral

      12/19/24 8:13:54 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Life Sciences downgraded by Goldman with a new price target

      Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25

      12/5/24 7:46:04 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciencesReleases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2

      5/21/25 4:05:00 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care